Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Payables (2016 - 2025)

Collegium Pharmaceutical has reported Payables over the past 10 years, most recently at $10.7 million for Q4 2025.

  • Quarterly results put Payables at $10.7 million for Q4 2025, up 170.95% from a year ago — trailing twelve months through Dec 2025 was $10.7 million (up 170.95% YoY), and the annual figure for FY2025 was $10.7 million, up 170.95%.
  • Payables for Q4 2025 was $10.7 million at Collegium Pharmaceutical, up from $7.6 million in the prior quarter.
  • Over the last five years, Payables for COLL hit a ceiling of $17.9 million in Q1 2025 and a floor of $2.4 million in Q2 2024.
  • Median Payables over the past 5 years was $6.3 million (2022), compared with a mean of $6.5 million.
  • Biggest five-year swings in Payables: tumbled 63.48% in 2023 and later skyrocketed 351.49% in 2025.
  • Collegium Pharmaceutical's Payables stood at $4.2 million in 2021, then decreased by 16.59% to $3.5 million in 2022, then soared by 148.77% to $8.7 million in 2023, then crashed by 54.74% to $3.9 million in 2024, then soared by 170.95% to $10.7 million in 2025.
  • The last three reported values for Payables were $10.7 million (Q4 2025), $7.6 million (Q3 2025), and $10.9 million (Q2 2025) per Business Quant data.